证券代码：688799 证券简称：华纳药厂 公告编号：2026-006 湖南华纳大药厂股份有限公司 自愿披露关于子公司通过巴西国家卫生监督局GMP认证的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 认证范围：化学原料药：磷霉素氨丁三醇 有效期限：2028年1月19日 发证机关：巴西国家卫生监督局（ANVISA） 二、药品相关情况 磷霉素氨丁三醇是磷霉素氨丁三醇散等制剂产品的原料药，制剂产品主要用于治疗敏感的大肠埃希氏 菌、粪肠球菌、肺炎克雷伯菌、枸橼酸杆菌属、肠杆菌属、奇异变形杆菌引起的急性单纯性尿路感染、 无症状菌尿症等。 近日，湖南华纳大药厂股份有限公司（以下简称"公司"）全资子公司湖南华纳大药厂手性药物有限公司 （以下简称"手性药物公司"）收到巴西国家卫生监督局（ANVISA）签发的药品生产质量管理规范 （GMP）认证证书。现将相关情况公告如下： 一、证书基本信息 生产企业：湖南华纳大药厂手性药物有限公司 生产地址：湖南省长沙市望城区铜官循环经济工业基地铜官大道139号 认证编号：1435341/23-6 湖南 ...

今日聚焦 1、寒武纪：2025年净利润20.59亿元，实现扭亏为盈 寒武纪2月27日公告，公司2025年实现营业收入649,719.62万元，较上年同期增加532,273.18万元，同比 增长453.21%。公司归属于母公司所有者的净利润为205,922.85万元，较上年同期扭亏为盈，主要系本 期营业收入大幅增长所致。报告期内，受益于人工智能行业算力需求的持续攀升，公司凭借产品的优异 竞争力持续拓展市场，积极推动人工智能应用场景落地，使得本期收入规模较上年同期大幅增长。 2、沐曦股份：2025年亏损同比收窄44.53%，公司GPU产品出货量显著增长 沐曦股份2月27日公告，公司2025年实现营业总收入164,408.55万元，较上年同期增长121.26%；实现归 属于母公司所有者的净利润-78,145.20万元，较上年同期亏损收窄44.53%；实现归属于母公司所有者的 扣除非经常性损益的净利润-82,170.63万元，较上年同期亏损收窄21.28%。报告期内，随着公司产品及 服务获得下游客户的广泛认可与持续采购，公司GPU产品出货量显著增长，带动收入规模较上年同期实 现显著增加。 3、摩尔线程：2025年亏损 ...

证券代码：688799 证券简称：华纳药厂 公告编号：2026-006 湖南华纳大药厂股份有限公司 自愿披露关于子公司通过巴西国家卫生监督局 GMP 认证的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，湖南华纳大药厂股份有限公司（以下简称"公司"）全资子公司湖南 华纳大药厂手性药物有限公司（以下简称"手性药物公司"）收到巴西国家卫生 监督局（ANVISA）签发的药品生产质量管理规范（GMP）认证证书。现将相关 情况公告如下： 一、证书基本信息 生产企业：湖南华纳大药厂手性药物有限公司 三、对公司的影响及风险提示 生产地址：湖南省长沙市望城区铜官循环经济工业基地铜官大道 139 号 认证编号：1435341/23-6 认证范围：化学原料药：磷霉素氨丁三醇 有效期限：2028 年 1 月 19 日 发证机关：巴西国家卫生监督局（ANVISA） 本次手性药物公司磷霉素氨丁三醇原料药顺利通过巴西国家卫生监督局的 GMP 认证，为该产品成功进入巴西市场创造了条件，对其进一步拓展巴西市场 和其他国际市场奠定坚实基础，有利于 ...

格隆汇2月27日｜华纳药厂(688799.SH)公告称，公司全资子公司湖南华纳大药厂手性药物有限公司收到 巴西国家卫生监督局签发的药品生产质量管理规范（GMP）认证证书，认证范围为化学原料药：磷霉 素氨丁三醇，有效期至2028年1月19日。该认证为该产品成功进入巴西市场创造了条件，有利于提升公 司的国际竞争力。但医药产品的国际原料药业务易受国家政策、海外市场环境变化等因素影响，具有一 定的不确定性。 ...

华纳药厂公告称，其全资子公司手性药物公司收到巴西国家卫生监督局签发的药品生产质量管理规范 （GMP）认证证书，认证范围为化学原料药磷霉素氨丁三醇，有效期至2028年1月19日。磷霉素氨丁三 醇是治疗尿路感染等制剂产品的原料药。此次认证为产品进入巴西市场创造条件，利于拓展国际市场、 提升国际竞争力，但国际原料药业务受政策和市场环境影响，有不确定性。 ...

Core Viewpoint - Warner Pharmaceuticals reported a revenue of 1.516 billion yuan for the year 2025, marking a year-on-year growth of 7.26% and a net profit attributable to the parent company of 241 million yuan, which represents a significant increase of 46.95% [1] Revenue Growth - The increase in total revenue is attributed to the growth in sales of formulation products, active pharmaceutical ingredients, intermediates, and technical service income [1] Net Profit Analysis - The rise in net profit attributable to the parent company is primarily influenced by investment income [1] - However, the net profit excluding non-recurring gains and losses decreased due to the accrual of stock incentive expenses; after adjusting for these expenses, the net profit attributable to the parent company was 182 million yuan, reflecting a year-on-year increase of 31.57% [1]

Financial Data Summary - The company reported preliminary financial data for the year 2025, with total revenue of 1.516 billion yuan, representing a year-on-year increase of 7.26% [1] - The net profit attributable to the parent company was 241 million yuan, showing a significant year-on-year growth of 46.95% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 130 million yuan, which reflects a decrease of 6.01% compared to the previous year [1] - Total assets at the end of the reporting period reached 3.053 billion yuan, marking a year-on-year increase of 24.11% [1] - The equity attributable to the parent company was 2.046 billion yuan, up 13.44% year-on-year [1] Performance Drivers - The increase in revenue was primarily driven by growth in sales of formulation products, raw materials, intermediate products, and technical service income [2] - The rise in net profit attributable to the parent company was mainly influenced by investment income [2] - The decline in net profit after deducting non-recurring gains and losses was attributed to the impact of stock incentive expenses; excluding these expenses, the adjusted net profit would have been 182 million yuan, an increase of 31.57% year-on-year [2] Significant Changes in Financial Metrics - Operating profit increased by 51.53% year-on-year, while total profit rose by 51.88% [3] - The basic earnings per share grew by 47.20% year-on-year, largely due to the strategic investment and restructuring of Shanghai Zhigen Pharmaceutical Technology Co., Ltd., which resulted in the company no longer consolidating it in its financial statements [3] - The company's share capital increased by 40.00% due to a capital reserve conversion, raising the total shares from 93.8 million to 131.32 million [3]

北京商报讯（记者 丁宁）2月13日晚间，华纳药厂（688799）发布2025年业绩快报显示，公司2025年度 实现营业收入15.16亿元，同比增长7.26%；归属净利润为2.41亿元，同比增长46.95%。 华纳药厂表示，报告期内，公司营业收入增长主要系公司制剂产品、原料药及中间体产品销售收入增长 以及技术服务收入增长共同所致；归属净利润增加主要是受投资收益影响。 ...

Group 1 - RuiLian New Materials reported a total operating revenue of 1.677 billion yuan for 2025, an increase of 14.95% year-on-year, with a net profit of 311 million yuan, up 23.48% year-on-year [1] - China Shenhua's subsidiary, Guoneng Qingyuan Power, successfully put its fourth generator unit into commercial operation, expected to provide approximately 20 billion kWh of clean energy annually [2] - Qijiang Airlines announced a 6.04% year-on-year decline in passenger turnover for January 2026, with a passenger load factor of 84.03%, up 1.61% year-on-year [3] Group 2 - QiZheng Tibetan Medicine reported a total operating revenue of 2.416 billion yuan for 2025, a year-on-year increase of 3.34%, with a net profit of 646 million yuan, up 10.98% year-on-year [5] - QiaoYin Co. announced the termination of its artificial intelligence industry headquarters project due to changes in investment cooperation conditions [6] - New Point Software plans to use 90.81 million yuan of surplus raised funds for new projects, including AI-driven software development [7] Group 3 - High Measurement Co. announced plans for major shareholders and executives to reduce their holdings by up to 3.19% of the company's shares [8] - SAIC Group's subsidiary plans to establish a private equity fund with an initial scale of 2.5 billion yuan, focusing on solid-state batteries and chip localization [9] - Tianqi Lithium announced the resignation of its deputy general manager due to personal career planning [10] Group 4 - ZhongKong Technology reported a total operating revenue of 8.051 billion yuan for 2025, a decrease of 11.90%, with a net profit of 450 million yuan, down 59.70% year-on-year [11] - Spring Airlines reported a 6.28% year-on-year increase in total passenger volume for January 2026, with a total available ton-kilometers of 57,008.37 [12] - Qifan Cable's controlling shareholder reduced its stake by 3% through various trading methods [13] Group 5 - China Chemical signed contracts worth a total of 36.925 billion yuan in January 2026, with significant contracts exceeding 5 billion yuan totaling 11.371 billion yuan [19] - SaiTuo Bio received a CEP certificate for its raw material drug Betamethasone, which is used to treat allergies and autoimmune inflammation [20] - Giant Star Agriculture reported a sales revenue of 649 million yuan from commodity fat pigs in January 2026, with a sales volume of 404,400 pigs [23] Group 6 - Qinglong Pipe Industry's subsidiary won a 146 million yuan pipeline project [24] - Changshan Pharmaceutical announced that some of its products are expected to be selected for national centralized procurement [26] - Yangdian Technology completed the transfer of 12.96% of its shares through an agreement [27] Group 7 - Deepin Technology's investment fund introduced new limited partners and adjusted the capital contributions of some partners [28] - Qingyun Technology plans to pledge 25% of its shares for a loan application of up to 30 million yuan [29] - LaiMei Pharmaceutical reported a 57.20% year-on-year decline in net profit for 2025 [30] Group 8 - YouLiDe reported a 16.88% year-on-year decline in net profit for 2025, with total operating revenue of 1.221 billion yuan, up 7.99% [31] - Warner Pharmaceutical reported a net profit of 241 million yuan for 2025, an increase of 46.95% year-on-year [32] - LianRui New Materials reported a net profit of 293 million yuan for 2025, an increase of 16.42% year-on-year [33] Group 9 - HuaQin Technology expects a 24.28% year-on-year decrease in net profit for 2025, with projected revenue of 1.251 billion yuan, up 9.83% [34] - QiPai Technology's shareholder subscribed for 6.3 million shares, accounting for 5.49% of the total share capital [35] - Qilin Security's shareholders completed their planned share reductions without exceeding the original plan [36] Group 10 - Dameng Data announced the lifting of the detention of its senior vice president, allowing him to resume his duties [37] - Haiyou Engineering won a contract for the "NFPS COMP5" project worth approximately 4 billion USD, with the company's share exceeding 800 million USD [38] - Yatai Group plans to sell 20.81% of its shares in Northeast Securities, pending confirmation of financial statements [39]

Group 1 - The core viewpoint of the article is that Warner Pharmaceuticals announced its financial results for the fiscal year 2025, showing significant growth in both revenue and net profit [2] - The company achieved an operating revenue of 1,515.59 million yuan, representing a year-on-year increase of 7.26% [2] - The net profit attributable to the parent company was 241.47 million yuan, reflecting a substantial year-on-year growth of 46.95% [2]